- b) collecting from said first subject a postimmune serum or plasma, or IgG isolated therefrom; and,
- c) administering to said second subject an amount of said serum or plasma or IgG isolated therefrom that is effective in conferring passive protection against a infection by heterologous Gram-negative bacteria or against lipopolysaccharide (LPS) endotoxin-mediated pathology.
- 20. Serum, plasma or specific polyclonal antibody obtained from a subject immunized with a vaccine according to claim 1.--